Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is ...

Hims & Hers Health stock plummeted after an FDA decision that prevents the company from selling compounded semaglutide. The company still expects to deliver strong revenue growth, though ...

Their tight supply had allowed Hims & Hers and others to sell cheaper versions of Novo's semaglutide. Hims & Hers said in February it cannot guarantee to continue to sell compounded semaglutide ...

In May, Hims & Hers started prescribing compounded semaglutide, the active ingredient in Novo Nordisk's GLP-1 weight loss medications Ozempic and Wegovy. The offering was immensely popular and ...

As the telehealth industry has grown, Hers has followed suit. It has expanded its offerings to include weight loss, focusing on prescription medications, including its own compounded semaglutide ...

The bank assigned a price target of $22 for Hims & Hers, implying a downside of around 25%. To demonstrate the value of its loss, compounded semaglutide drug sales brought in $225 million in ...

Much of the excitement over Hims & Hers has been connected to the company's sales of compounded versions of GLP-1 inhibitor semaglutide. Novo Nordisk markets semaglutide as a treatment for type 2 ...